A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Clinical trial NCT07213960 · SUSPENDED
Trial details
- NCT number
- NCT07213960
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- SUSPENDED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-12-01
- Primary completion
- 2029-10-01
- Enrollment
- 270
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.